비교리스트

 카트 문의
시장보고서
상품코드
1351394

세계의 환자유래이종이식(PDX) 모델 시장 : 종양 유형별, 모델별, 최종사용자별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2023-2030년)

Patient Derived Xenograft (PDX) Model Market, By Tumor Type, By Model, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 246 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 환자유래이종이식(PDX) 모델 시장 규모는 2022년 2억 9,060만 달러로 2023년부터 2030년까지 연평균 13.2%의 성장률을 기록할 것으로 예상됩니다.

환자유래이종이식(PDX) 모델 시장 - 시장 역학

  • 세계 암 유병률 증가로 시장 성장 견인
  • 전 세계적으로 암의 유병률이 증가함에 따라 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 미국 국립암연구소(National Cancer Institutes)가 발표한 보고서에 따르면, 2022년 1월 기준 미국 내 암 생존자 수는 1,810만 명에 달합니다. 이는 전체 인구의 약 5.4%에 해당합니다. 미국에서는 62만 3,405명이 전이성 유방암, 전립선암, 폐암, 대장암, 방광암, 흑색종으로 고통받고 있으며, 2025년에는 69만 3,452명으로 늘어날 것으로 예측됩니다. 또한 영국 암 연구소의 자료에 따르면, 발병률이 안정되고 인구 증가와 고령화가 현재 속도로 지속된다면, 2040년까지 전 세계적으로 매년 2,800만 명의 암 환자가 새로 발생할 것으로 예측됩니다. 이는 2020년 대비 54.9% 증가한 수치이며, 여성(48.8% 증가)보다 남성(60.6% 증가)의 증가율이 더 높을 것으로 예측됩니다. 따라서 앞서 언급한 사실은 예측 기간 동안 시장 성장을 촉진할 것입니다.

환자유래이종이식(PDX) 모델 시장 - 세분화 분석

  • 환자유래이종이식(PDX) 모델 세계 시장은 종양 유형, 모델, 최종사용자 및 지역을 기준으로 세분화됩니다.
  • 종양 유형에 따라 세계 환자유래이종이식(PDX) 모델 시장은 전립선암, 췌장암, 폐암, 유방암, 기타로 분류됩니다. 예측 기간 동안 유방암 분야가 시장을 주도할 것으로 예상됩니다. 유방암은 시대에 따라 발견 및 치료 방법이 크게 개선되었음에도 불구하고 여전히 전 세계 여성 사망 원인 1위를 차지하고 있습니다. 유방암을 포함한 종양은 매우 다양한 집단으로 구성되어 있기 때문에 현재의 의약품으로 종양을 파괴하는 것은 어려운 과제입니다. 유방암의 종양 간 이질성으로 인해 in vitro나 in vivo에서 생성된 세포주 등 일반적으로 사용되는 암 모델을 통해 치료 효과를 정확하게 예측하는 것도 어렵습니다. 이에 따라 인간 악성 종양의 기원의 다양성을 보다 현실적으로 묘사하기 위해 PDX 모델이 만들어지고 있습니다. 이러한 모델을 통해 유방암 치료법을 개선할 수 있을 것으로 기대됩니다. 이는 예측 기간 동안 이 분야의 성장을 견인할 것입니다.
  • 환자유래이종이식(PDX) 모델 시장 - 지리적 인사이트
  • 지역적으로 이 시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카로 나뉩니다. 이 지역은 사업 운영 국가에 따라 더 세분화됩니다. 북미는 암 유병률 증가로 인해 예측 기간 동안 시장을 지배할 것으로 예상됩니다. 또한, R&D 투자 증가도 업계 확장을 촉진하는 중요한 요소입니다. 또한, 이 지역에는 주요 기업들이 존재하기 때문에 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 2023년 4월, 2023년 미국암연구협회(AACR) 연례회의에서 패러다임을 바꾸는 치료제를 통해 암 환자의 미충족 의료 수요를 충족시키고자 하는 바이오제약 기업 빈서엑스 파마(Vincerx Pharma, Inc.)는 다양한 종양 유형에 걸친 PDX 마우스 모델 및 전이성 PDX 마우스 모델에서 VIP236 단제 치료의 전임상 데이터를 포스터로 발표했습니다. 따라서 이러한 노력은 이 지역의 시장 성장을 촉진할 것으로 기대됩니다.

환자유래이종이식(PDX) 모델 시장 - 경쟁 상황

시장에서 활동하는 주요 기업은 다음과 같습니다: WuXi AppTec, XenTech, Crown Bioscience, Altogen Labs, Envigo, Charles River Laboratories, Oncodesign, Hera Biolabs, The Jackson Laboratory, Abnova Corp.

목차

제1장 환자유래이종이식(PDX) 모델 시장 개요

  • 조사 범위
  • 시장 추정 연수

제2장 주요 요약

  • 시장 내역
  • 경쟁 인사이트

제3장 환자유래이종이식(PDX) 모델 주요 시장 동향

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 향후 시장 동향

제4장 환자유래이종이식(PDX) 모델 산업 연구

  • PEST 분석
  • Porter's Five Forces 분석
  • 성장 전망 매핑
  • 규제 체계 분석

제5장 환자유래이종이식(PDX) 모델 시장 : COVID-19의 영향 분석

  • 신종 코로나바이러스 감염증 이전의 영향 분석
  • 신종 코로나바이러스 감염증 후의 영향 분석

제6장 환자유래이종이식(PDX) 모델 시장 상황

  • 환자유래이종이식(PDX) 모델 시장 점유율 분석, 2022년
  • 주요 제조업체별 내역 데이터
    • 기존 기업 분석
    • 신흥 기업 분석

제7장 환자유래이종이식(PDX) 모델 시장 - 종양 유형별

  • 개요
    • 종양 유형별 부문 점유율 분석
    • 전립선암
    • 췌장암
    • 폐암
    • 유방암
    • 기타

제8장 환자유래이종이식(PDX) 모델 시장 - 모델별

  • 개요
    • 모델별 부문 점유율 분석
    • 마우스
    • 쥐

제9장 환자유래이종이식(PDX) 모델 시장 - 최종사용자별

  • 개요
    • 최종사용자별 부문 점유율 분석
    • 제약회사·바이오의약품 회사
    • 학술연구기관
    • CRO·CDMO

제10장 환자유래이종이식(PDX) 모델 시장 - 지역별

  • 서론
  • 북미
    • 개요
    • 북미의 주요 제조업체
    • 미국
    • 캐나다
  • 유럽
    • 개요
    • 유럽의 주요 제조업체
    • 독일
    • 이탈리아
    • 영국
    • 프랑스
    • 러시아
    • 네덜란드
    • 스웨덴
    • 폴란드
    • 기타
  • 아시아태평양
    • 개요
    • 아시아태평양의 주요 제조업체
    • 인도
    • 중국
    • 일본
    • 한국
    • 호주
    • 태국
    • 인도네시아
    • 필리핀
    • 기타
  • 라틴아메리카
    • 개요
    • 라틴아메리카의 주요 제조업체
    • 브라질
    • 멕시코
    • 아르헨티나
    • 콜롬비아
    • 기타
  • 중동 및 아프리카
    • 개요
    • 중동 및 아프리카의 주요 제조업체
    • 사우디아라비아
    • 아랍에미리트
    • 이스라엘
    • 터키
    • 알제리
    • 이집트
    • 기타

제11장 주요 벤더 분석 - 환자유래이종이식(PDX) 모델 업계

  • 경쟁 대시보드
  • 기업 개요
    • WuXi AppTec
    • XenTech
    • Crown Bioscience
    • Altogen Labs
    • Envigo
    • Charles River Laboratories
    • Oncodesign
    • Hera Biolabs
    • The Jackson Laboratory
    • Abnova Corp.

제12장 애널리스트의 전방위 전망

ksm 23.10.27

REPORT HIGHLIGHT

Patient Derived Xenograft (PDX) Model Market size was valued at USD 290.6 Million in 2022, expanding at a CAGR of 13.2% from 2023 to 2030.

Patient-derived xenografts (PDX) are cancer models in which a patient's tumor tissue or cells are implanted into immunocompromised or humanized mice. This procedure involves xenotransplantation. To maintain the development of cancer after it has been removed from a patient, PDX models are employed. This allows for the monitoring of tumor development in the lab, including how it responds to various therapy choices. A PDX model from a given patient can be evaluated against a variety of medicines in a 'personalized oncology' approach, or cohorts of PDX models can be used to assess the therapeutic effectiveness of a drug against distinct forms of cancer.

Patient Derived Xenograft (PDX) Model Market - Market Dynamics:

  • The growing prevalence of cancer across the globe drives the market growth
  • The growing prevalence of cancer across the globe is expected to drive market growth during the forecast period. For instance, according to the report published by National Cancer Institutes, there would be 18.1 million cancer survivors in the US as of January 2022. This is equivalent to around 5.4% of the total population. In the United States, 623,405 persons have metastatic breast, prostate, lung, colorectal, bladder, or melanoma, and by the year 2025, that number is projected to rise to 693,452. Moreover, as per the data by Cancer Research UK, it is anticipated that there will be 28 million new cancer cases globally each year by 2040 if incidence remains steady and population growth and ageing continue at current rates. This is a 54.9% increase over 2020, and it is predicted to be larger in males (60.6% increase) than in women (48.8% increase). Thus, the aforementioned facts drive the market growth during the forecast period.

Patient Derived Xenograft (PDX) Model Market - Key Insights:

  • As per the analysis shared by our research analyst, the global Patient Derived Xenograft (PDX) Model market is estimated to grow annually at a CAGR of around 13.2% over the forecast period (2023-2030)
  • Patient Derived Xenograft (PDX) Model industry is projected to grow at a significant rate owing to the growing prevalence of cancer.
  • Based on the tumor type, the breast cancer segment is expected to dominate the market over the forecast period.
  • Based on region, North America is expected to dominate the market over the forecast period.

Patient Derived Xenograft (PDX) Model Market- Segmentation Analysis:

  • The Global Patient Derived Xenograft (PDX) Model Market is segmented based on tumor type, model, end user and Region.
  • Based on the tumor type, the global Patient Derived Xenograft (PDX) Model market is segmented into prostate cancer, pancreatic cancer, lung cancer, breast cancer and others. The breast cancer segment is expected to dominate the market during the forecast period. Breast cancer still ranks as the leading cause of death for women worldwide, despite major improvements in detection and treatment methods over time. With current medicines, it is challenging to destroy tumors since they are made up of populations that are extremely varied, including those of breast cancer. Due to the inter-tumor heterogeneity of breast cancer, it is also difficult to accurately predict therapeutic efficacy using commonly used cancer models, such as cell lines created in vitro and in vivo. As a result, PDX models have been created to more realistically depict the variability of the origins of human malignancies. These models are expected to improve breast cancer therapy modalities. Thereby, driving the segment growth over the forecast period.

Patient Derived Xenograft (PDX) Model Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market over the forecast period due to the increasing prevalence of cancer. Moreover, the increasing R&D investments are also an important factor that propels the industry expansion. Furthermore, the presence of key players in the region is expected to propel the market growth. For instance, in April 2023, at the 2023 American Association for Cancer Research (AACR) Annual Meeting, Vincerx Pharma, Inc., a biopharmaceutical company aiming to address the unmet medical needs of cancer patients through paradigm-shifting therapeutics, presented a poster of preclinical data of VIP236 monotherapy treatment in PDX and metastatic PDX mouse models across various tumor types. Thus, this kind of initiative is expected to drive market growth in the region.

Patient Derived Xenograft (PDX) Model Market- Competitive Landscape:

The key players operating in the market are: WuXi AppTec, XenTech, Crown Bioscience, Altogen Labs, Envigo, Charles River Laboratories, Oncodesign, Hera Biolabs, The Jackson Laboratory and Abnova Corp.

Recent Developments:

In July 2022, GemPharmatech (GemPharmatech Co., Ltd.) announced that it has entered into a strategic license agreement with Charles River Laboratories, Inc. for the exclusive distribution of its next-generation NOD CRISPR Prkdc Il2r gamma (NCG) mouse lines in North America. The goal of this agreement is to speed up the development of novel therapeutics for a variety of unmet medical needs, particularly in immuno-oncology. To produce models that will be sold starting in 2023, Charles River will create foundation colonies.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PATIENT DERIVED XENOGRAFT (PDX) MODEL MARKET KEY PLAYERS

  • WuXi AppTec
  • XenTech
  • Crown Bioscience
  • Altogen Labs
  • Envigo
  • Charles River Laboratories
  • Oncodesign
  • Hera Biolabs
  • The Jackson Laboratory
  • Abnova Corp.

GLOBAL PATIENT DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE

  • Prostate Cancer
  • Pancreatic Cancer
  • Lung Cancer
  • Breast Cancer
  • Others

GLOBAL PATIENT DERIVED XENOGRAFT (PDX) MODEL MARKET, BY MODEL

  • Mice
  • Rats

GLOBAL PATIENT DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER

  • Pharmaceutical And Biopharmaceutical Companies
  • Academic & Research Institutes
  • CROs & CDMOs

GLOBAL PATIENT DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Russia
    • Netherlands
    • Sweden
    • Poland
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • South Korea
    • Japan
    • Australia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Rest of LATAM
  • The Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Turkey
    • Algeria
    • Egypt
    • Rest of MEA

Table of Contents

1. Patient Derived Xenograft (PDX) Model Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Patient Derived Xenograft (PDX) Model Market Snippet by Tumor Type
    • 2.1.2. Patient Derived Xenograft (PDX) Model Market Snippet by Model
    • 2.1.3. Patient Derived Xenograft (PDX) Model Market Snippet by End User
    • 2.1.4. Patient Derived Xenograft (PDX) Model Market Snippet by Country
    • 2.1.5. Patient Derived Xenograft (PDX) Model Market Snippet by Region
  • 2.2. Competitive Insights

3. Patient Derived Xenograft (PDX) Model Key Market Trends

  • 3.1. Patient Derived Xenograft (PDX) Model Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Patient Derived Xenograft (PDX) Model Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Patient Derived Xenograft (PDX) Model Market Opportunities
  • 3.4. Patient Derived Xenograft (PDX) Model Market Future Trends

4. Patient Derived Xenograft (PDX) Model Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Patient Derived Xenograft (PDX) Model Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Patient Derived Xenograft (PDX) Model Market Landscape

  • 6.1. Patient Derived Xenograft (PDX) Model Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Patient Derived Xenograft (PDX) Model Market - By Tumor Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Tumor Type, 2022 & 2030 (%)
    • 7.1.2. Prostate Cancer
    • 7.1.3. Pancreatic Cancer
    • 7.1.4. Lung Cancer
    • 7.1.5. Breast Cancer
    • 7.1.6. Others

8. Patient Derived Xenograft (PDX) Model Market - By Model

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Model, 2022 & 2030 (%)
    • 8.1.2. Mice
    • 8.1.3. Rats

9. Patient Derived Xenograft (PDX) Model Market - By End User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End User, 2022 & 2030 (%)
    • 9.1.2. Pharmaceutical And Biopharmaceutical Companies
    • 9.1.3. Academic & Research Institutes
    • 9.1.4. CROs & CDMOs

10. Patient Derived Xenograft (PDX) Model Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Patient Derived Xenograft (PDX) Model Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Patient Derived Xenograft (PDX) Model Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Patient Derived Xenograft (PDX) Model Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Patient Derived Xenograft (PDX) Model Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Patient Derived Xenograft (PDX) Model Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Tumor Type, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Model, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Patient Derived Xenograft (PDX) Model Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. WuXi AppTec
    • 11.2.2. XenTech
    • 11.2.3. Crown Bioscience
    • 11.2.4. Altogen Labs
    • 11.2.5. Envigo
    • 11.2.6. Charles River Laboratories
    • 11.2.7. Oncodesign
    • 11.2.8. Hera Biolabs
    • 11.2.9. The Jackson Laboratory
    • 11.2.10. Abnova Corp.

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제